FIELD: medicine.
SUBSTANCE: invention relates to a compound of formula (I') having the properties of an inhibitor of the IKAROS family zinc finger protein 2 (IKZF2), or a pharmaceutically acceptable salt thereof, a pharmaceutical composition based on them for the treatment of a disease or disorder affected by a decrease in IKZF2 protein levels, a method for destroying IKZF2, a method for modulating and reducing IKZF2 protein levels, a method of treatment and their use in the treatment of a disease or disorder affected by modulation of IKZF2 protein levels. In the general formula (I') each of X1 and X2 independently represents H or halogen; Rx is H;
R1 is either or The remaining values of the radicals are indicated in the claims.
EFFECT: obtaining an inhibitor of the IKAROS family zinc finger protein 2 (IKZF2), or a pharmaceutically acceptable salt thereof.
30 cl, 14 tbl, 185 ex
Title | Year | Author | Number |
---|---|---|---|
3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USE THEREOF IN TREATING DISEASES ASSOCIATED WITH ZINC FINGER PROTEIN 2 OF IKAROS (IKZF2) FAMILY | 2019 |
|
RU2815714C2 |
COMPOSITIONS AND METHODS OF SELECTIVE PROTEIN DEGRADATION | 2018 |
|
RU2811700C2 |
ANTIBODY AND DRUG CONJUGATES (ADC) AND ANTIBODY AND PRODRUG CONJUGATES (APDC) CONTAINING ENZYMATICALLY CLEAVABLE GROUPS | 2016 |
|
RU2751512C2 |
FGF21 DERIVATIVES AND USE THEREOF | 2015 |
|
RU2729011C2 |
COMPOSITION FOR TREATING IGF-1R EXPRESSING CANCER | 2016 |
|
RU2728568C2 |
ANTIBODY TO B7H3-EXATECAN ANALOGUE CONJUGATE AND ITS USE IN MEDICINE | 2019 |
|
RU2785664C2 |
N1/N2-LACTAM ACETYL-CoA-CARBOXYLASE INHIBITORS | 2011 |
|
RU2540337C2 |
CONJUGATES OF BINDER AND ACTIVE SUBSTANCE (ADC) HAVING ENZYMATICALLY CLEAVABLE GROUPS | 2017 |
|
RU2761390C2 |
ANTIBODY-STING AGONIST CONJUGATES AND USE THEREOF IN IMMUNOTHERAPY | 2020 |
|
RU2826228C2 |
SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES | 2019 |
|
RU2815199C2 |
Authors
Dates
2023-06-07—Published
2019-07-08—Filed